1. Home
  2. ALLO

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Founded: 2017 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 495.1M IPO Year: 2018
Target Price: $13.18 AVG Volume (30 days): 2.3M
Analyst Decision: Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.82 EPS Growth: N/A
52 Week Low/High: $2.23 - $6.05 Next Earning Date: 05-13-2024
Revenue: $65,000 Revenue Growth: -48.00%
Revenue Growth (this year): -40.76% Revenue Growth (next year): 9181.47%

Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Parker Geoffrey M. ALLO CHIEF FINANCIAL OFFICER Jan 30 '24 Buy $3.60 190 $683.05 819,590 SEC Form 4
MESSEMER DEBORAH M. ALLO Director Dec 18 '23 Sell $2.70 18,640 $50,316.82 62,456 SEC Form 4

Share on Social Networks: